What type of prostate cancer is Erleada used to treat?
Medically reviewed by Drugs.com. Last updated on Sep 19, 2019.
Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.
Non-metastatic castration-resistant prostate cancer (NM-CRPC) refers to prostate cancer that no longer responds to androgen deprivation therapy (ADT) or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body.
Erleada is an androgen receptor inhibitor. It works by blocking the effect of androgens on the tumor. Androgens, such as testosterone, can promote tumor growth.
Erleada is taken orally, once daily, with or without food.
Related Medical Questions
- Oxycodone vs Hydrocodone - How do they compare?
- Vicodin vs Percocet: What's the difference?
- Is Sprycel a chemotherapy drug?
- How does Ibrance kill cancer?
- Can Darzalex cure Multiple Myeloma?
- What are the side effects of marijuana?
- My stool has changed color. What does it mean?
- Does Cabometyx (cabozantinib) cure cancer?
- Is Darzalex chemotherapy?
- Is lenvatinib / pembrolizumab used in endometrial cancer?
- How are axitinib and pembrolizumab used in kidney cancer?
- How effective is Herceptin for Breast & Gastric Cancer?
- How effective is Alecensa for ALK-positive NSCLC?
- What type of cancer is Tecentriq used to treat?
- What type of drug is Libtayo?